- Home
- MAIA vs ACRV Comparison
MAIA vs ACRV Comparison
Compare MAIA & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- ACRV
- Stock Information
- Founded
- MAIA 2018
- ACRV 2018
- Country
- MAIA United States
- ACRV United States
- Employees
- MAIA N/A
- ACRV N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- MAIA Health Care
- ACRV Health Care
- Exchange
- MAIA Nasdaq
- ACRV Nasdaq
- Market Cap
- MAIA 44.9M
- ACRV 47.8M
- IPO Year
- MAIA 2022
- ACRV 2022
- Fundamental
- Price
- MAIA $1.11
- ACRV $1.87
- Analyst Decision
- MAIA
- ACRV Buy
- Analyst Count
- MAIA 0
- ACRV 6
- Target Price
- MAIA N/A
- ACRV $17.75
- AVG Volume (30 Days)
- MAIA 747.3K
- ACRV 1.1M
- Earning Date
- MAIA 11-07-2025
- ACRV 11-07-2025
- Dividend Yield
- MAIA N/A
- ACRV N/A
- EPS Growth
- MAIA N/A
- ACRV N/A
- EPS
- MAIA N/A
- ACRV N/A
- Revenue
- MAIA N/A
- ACRV N/A
- Revenue This Year
- MAIA N/A
- ACRV N/A
- Revenue Next Year
- MAIA N/A
- ACRV $805.34
- P/E Ratio
- MAIA N/A
- ACRV N/A
- Revenue Growth
- MAIA N/A
- ACRV N/A
- 52 Week Low
- MAIA $1.05
- ACRV $1.05
- 52 Week High
- MAIA $3.48
- ACRV $8.74
- Technical
- Relative Strength Index (RSI)
- MAIA 34.52
- ACRV 48.13
- Support Level
- MAIA $1.05
- ACRV $1.91
- Resistance Level
- MAIA $1.35
- ACRV $2.46
- Average True Range (ATR)
- MAIA 0.10
- ACRV 0.17
- MACD
- MAIA -0.03
- ACRV -0.02
- Stochastic Oscillator
- MAIA 12.85
- ACRV 15.69
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.